维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

9篇 您的检索式：作者名="PRIYA M L"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Association of interleukin-10 gene promoter poIy- morphism in allergic patients显示文摘	GADDAM S L PRIYA V H S BABU B M V S	2012	Genet Test Mol Bi- omarkers2012，16，：	1
	2	RAPD and ISSR marker-based comparative evaluation of genetic diversity among indian germplasms of euryale ferox: an aquatic food plant显示文摘	Kumar H Priya P Singh N Kumar M Choudhary B K Kumar L Singh I S Kumar N	2016	Applied Biochemistry and Biotechnology2016，11，01：	1
	3	A database of bacterial lipoproteins(DOLOP)with functional assignments to predicted lipoproteins显示文摘	BABU M M PRIYA M L SELVAN A T	2006	Journal of bacteriology2006，188，8：	1
	4	A Database of Bacterial Lipoproteins (DOLOP) With Functional Assignments to Predicted Lipoproteins显示文摘	Babu M M Priya M L Selvan A T	2006	Journal of Bacteriology2006，188，：	1
	5	Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs.	Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch	2017	World Journal of Virology2017，6，4：	1
	6	Preparation of protoplasts from the cyano- bacterium Spirulina platensis and a novel viability assay显示文摘	Priya Sethu K M Prabha T N venkataraman L V	1994	Lett in Appl Microbiol1994，16，：	1
	7	Higher than optimum temperature under CO2 enrichment influences stomata anatomical characters in rose (Rosa hybrida)显示文摘	Renu P Priya M Chacko M L	2007	Scientia Horticulturae2007，113，1：	1
	8	Intracellular disposal of incompletely folded humanα1-antitrypsin involves release from calnexin and post-translational trimming of asparaginc-linked oligosaccharides 显示文摘	Yan L Priya C Christopher M C	1997	The Journal of Biological Chemistry1997，272，12：	1
	9	Similarity-based rankingand query processing in multimedia databases显示文摘	Candan K S Li W S Priya M L	2000	Data &Knowledge Engineering2000，35，：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费